THU0129 Predictive value of cd19 serum levels for long term therapeutic response and utility as biomarker for optimisation, in rheumatoid arthritis patients treated with rituximab

• Published in: Annals of the rheumatic diseases Vol. 77; no. Suppl 2; p. 285
• Main Authors: Melchor, S., Rodríguez, E., Pablos, J.L., Carreira, P.E.
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2018
• Subjects: Antigens; Biomarkers; CD19 antigen; CD20 antigen; CD3 antigen; CD56 antigen; Immunoglobulin G; Immunotherapy; Infections; Long term; Lymphocytes B; Monoclonal antibodies; Remission; Rheumatoid arthritis; Rituximab; Serum levels

BackgroundRituximab (RTX) is a chimeric monoclonal antibody directed against CD20 antigens in B lymphocytes (BL) surface, producing selective depletion of BL, without affecting mature plasmatic cells. Current guidelines recommend optimisation of biologic therapy once remission has achieved in rheuma...